HRP20100621T1 - Etanolaminska sol od n-(metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida - Google Patents
Etanolaminska sol od n-(metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida Download PDFInfo
- Publication number
- HRP20100621T1 HRP20100621T1 HR20100621T HRP20100621T HRP20100621T1 HR P20100621 T1 HRP20100621 T1 HR P20100621T1 HR 20100621 T HR20100621 T HR 20100621T HR P20100621 T HRP20100621 T HR P20100621T HR P20100621 T1 HRP20100621 T1 HR P20100621T1
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- methylpyrazin
- pyridine
- methoxy
- phenyl
- Prior art date
Links
- -1 3-methoxy-5-methylpyrazin-2yl Chemical group 0.000 title 1
- 150000002169 ethanolamines Chemical class 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title 1
- NKFLEFWUYAUDJV-UHFFFAOYSA-N pyridine-3-sulfonamide Chemical compound NS(=O)(=O)C1=CC=CN=C1 NKFLEFWUYAUDJV-UHFFFAOYSA-N 0.000 title 1
- MUVIXLBNMQPGRV-UHFFFAOYSA-N 2-aminoethanol;n-(3-methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide Chemical compound NCCO.COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 MUVIXLBNMQPGRV-UHFFFAOYSA-N 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims 4
- FJHHZXWJVIEFGJ-UHFFFAOYSA-N N-(3-methoxy-5-methyl-2-pyrazinyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]-3-pyridinesulfonamide Chemical compound COC1=NC(C)=CN=C1NS(=O)(=O)C1=CC=CN=C1C1=CC=C(C=2OC=NN=2)C=C1 FJHHZXWJVIEFGJ-UHFFFAOYSA-N 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 229910016523 CuKa Inorganic materials 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 208000020816 lung neoplasm Diseases 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027452 Metastases to bone Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 238000002441 X-ray diffraction Methods 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 230000000683 nonmetastatic effect Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
N-(3-Metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamid etanolaminska sol. Patent sadrži još 20 patentnih zahtjeva.
Claims (21)
1. N-(3-Metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamid etanolaminska sol.
2. Sol prema zahtjevu 1, nadalje naznačena time da spoj je u osnovi kristaliničnog oblika.
3. Sol prema zahtjevu 2, nadalje naznačena time da spoj ima uzorak difrakcije X-zraka na prahu koji sadrži barem vrške sa 2-theta vrijednostima pri 8.9°, 10.9° i 18° mjereno korištenjem CuKa zračenja.
4. Sol prema zahtjevu 3, nadalje naznačena time da spoj ima uzorak difrakcije X-zraka na prahu koji sadrži barem vrške sa 2-theta vrijednostima pri 8,9°, 10.9°, 18°, 25.5°, 15.5° i 21.7° mjereno korištenjem CuKa zračenja.
5. Sol prema zahtjevu 4, nadalje naznačena time da spoj ima uzorak difrakcije X-zraka na prahu koji sadrži barem vrške sa 2-theta vrijednostima pri 8.9°, 10.9°, 18°, 25.5°, 15.5°, 21.7, 21.2°, 24.1° i 25.9° mjereno korištenjem CuKa zračenja.
6. Spoj prema zahtjevu 5, naznačen time da je uzorak difrakcije X-zraka u osnovi kako je definirano na slici 3 i/ili u Tabeli 3:
Tabela 3
[image]
7. Postupak za dobivanje N-(3-metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida naznačen time da sadrži upotrebu etanolamin za uklanjanje zaštite spoja prema formuli (II):
[image]
gdje Pg je pogodna dušikova zaštitna skupina.
8. Postupak prema zahtjevu 7 naznačen time da Pg je izobutoksikarbonil.
9. Postupak za proizvodnju N-(3-metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida u osnovi u obliku Oblika 1 naznačen time da sadrži:
(i) upotrebu etanolamina za uklanjanje zaštite spoja prema formuli (II):
[image]
gdje Pg je pogodna dušikova zaštitna skupina; koju slijedi
(ii) dodavanja rezultirajuće N-(3-metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridine-3-sulfonamidne etanolaminske soli u kiselinu.
10. Postupak prema zahtjevu 9 naznačen time da Pg je izobutoksikarbonil.
11. Postupak prema zahtjevu 9 ili zahtjevu 10 naznačen time da kiselina je octena kiselina.
12. Upotreba soli prema zahtjevu 1 naznačena time da je za dobivanje N-(3-metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridine-3-sulfonamida.
13. Upotreba soli prema zahtjevu 1 naznačena time da je za proizvodnju N-(3-metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridine-3-sulfonamida u osnovi u obliku Oblika 1.
14. Farmaceutski pripravak naznačen time da sadrži sol prema bilo kojem od zahtjeva 1-6 zajedno sa farmaceutski prihvatljivim otapalom ili nosačem.
15. Sol prema bilo kojem od zahtjeva 1-6 naznačena time da je za upotrebu kao lijek.
16. Upotreba soli prema bilo kojem od zahtjeva 1-6, naznačena time da je za proizvodnju lijeka za liječenja raka kod toplokrvnih životinja kao što je čovjek.
17. Upotreba prema zahtjevu 16 naznačena time da rak je rak jednjaka, mijelom, hepatocelularni rak, rak gušterače, rak grlića maternice, Ewingov tumor, neuroblastom, kapozni tumor, karcinom jajnika, karcinom dojke, rak debelog crijeva, rak prostate, rak mjehura, melanom, karcinom pluća - rak pluća ne malih stanica i rak pluća malih stanica, karcinom želuca, raka glave i vrata, rak bubrega, limfom i leukemija.
18. Upotreba prema zahtjevu 16 naznačena time da rak je rak prostate.
19. Upotreba prema bilo kojem od zahtjeva 16-18 naznačena time da rak je u metastaznom stanju.
20. Upotreba prema bilo kojem od zahtjeva 16-18 naznačena time da rak je u ne-metastaznom stanju.
21. Upotreba prema zahtjevu 16 naznačena time da rak je renalni, tiroidni, rak pluća, rak dojke ili rak prostate koji proizvodi koštane metastaze.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0514743.4A GB0514743D0 (en) | 2005-07-19 | 2005-07-19 | Salt |
| PCT/GB2006/002654 WO2007010235A1 (en) | 2005-07-19 | 2006-07-17 | Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl] phenyl) pyridine-3- sulphonamide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100621T1 true HRP20100621T1 (hr) | 2010-12-31 |
Family
ID=34897419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100621T HRP20100621T1 (hr) | 2005-07-19 | 2010-11-16 | Etanolaminska sol od n-(metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20080221124A1 (hr) |
| EP (1) | EP1904490B1 (hr) |
| JP (1) | JP5085544B2 (hr) |
| KR (1) | KR20080031042A (hr) |
| CN (1) | CN101223165B (hr) |
| AT (1) | ATE482952T1 (hr) |
| AU (1) | AU2006271420B2 (hr) |
| CA (1) | CA2615596A1 (hr) |
| CY (1) | CY1110942T1 (hr) |
| DE (1) | DE602006017220D1 (hr) |
| DK (1) | DK1904490T3 (hr) |
| ES (1) | ES2351442T3 (hr) |
| GB (1) | GB0514743D0 (hr) |
| HK (1) | HK1118276A1 (hr) |
| HR (1) | HRP20100621T1 (hr) |
| IL (1) | IL188389A0 (hr) |
| MX (1) | MX2008000889A (hr) |
| NO (1) | NO20080053L (hr) |
| PL (1) | PL1904490T3 (hr) |
| PT (1) | PT1904490E (hr) |
| SI (1) | SI1904490T1 (hr) |
| WO (1) | WO2007010235A1 (hr) |
| ZA (1) | ZA200800328B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| GB0914287D0 (en) * | 2009-08-14 | 2009-09-30 | Pci Biotech As | Compositions |
| CN102491973A (zh) * | 2011-12-15 | 2012-06-13 | 南京友杰医药科技有限公司 | Zd-4054的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5464853A (en) * | 1993-05-20 | 1995-11-07 | Immunopharmaceutics, Inc. | N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin |
| US5514691A (en) * | 1993-05-20 | 1996-05-07 | Immunopharmaceutics, Inc. | N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin |
| UA58494C2 (uk) * | 1995-06-07 | 2003-08-15 | Зенека Лімітед | Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну |
| US20020055457A1 (en) * | 2000-08-07 | 2002-05-09 | Janus Todd J. | Methods of treating cancer and the pain associated therewith using endothelin antagonists |
| US20030092757A1 (en) * | 2001-04-11 | 2003-05-15 | Amitabh Singh | Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer |
| DE10155076A1 (de) * | 2001-11-09 | 2003-05-22 | Merck Patent Gmbh | Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen |
| AU2002358390A1 (en) * | 2001-12-18 | 2003-06-30 | Astrazeneca Ab | Novel compounds |
| GB0219660D0 (en) * | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
-
2005
- 2005-07-19 GB GBGB0514743.4A patent/GB0514743D0/en not_active Ceased
-
2006
- 2006-07-17 MX MX2008000889A patent/MX2008000889A/es active IP Right Grant
- 2006-07-17 EP EP06755779A patent/EP1904490B1/en active Active
- 2006-07-17 KR KR1020087002607A patent/KR20080031042A/ko not_active Application Discontinuation
- 2006-07-17 CA CA002615596A patent/CA2615596A1/en not_active Abandoned
- 2006-07-17 PT PT06755779T patent/PT1904490E/pt unknown
- 2006-07-17 SI SI200630823T patent/SI1904490T1/sl unknown
- 2006-07-17 DE DE602006017220T patent/DE602006017220D1/de active Active
- 2006-07-17 DK DK06755779.3T patent/DK1904490T3/da active
- 2006-07-17 US US11/996,005 patent/US20080221124A1/en not_active Abandoned
- 2006-07-17 PL PL06755779T patent/PL1904490T3/pl unknown
- 2006-07-17 WO PCT/GB2006/002654 patent/WO2007010235A1/en active Application Filing
- 2006-07-17 AT AT06755779T patent/ATE482952T1/de active
- 2006-07-17 CN CN2006800261471A patent/CN101223165B/zh not_active Expired - Fee Related
- 2006-07-17 ES ES06755779T patent/ES2351442T3/es active Active
- 2006-07-17 AU AU2006271420A patent/AU2006271420B2/en not_active Ceased
- 2006-07-17 JP JP2008522051A patent/JP5085544B2/ja not_active Expired - Fee Related
-
2007
- 2007-12-24 IL IL188389A patent/IL188389A0/en unknown
-
2008
- 2008-01-04 NO NO20080053A patent/NO20080053L/no not_active Application Discontinuation
- 2008-01-10 ZA ZA200800328A patent/ZA200800328B/xx unknown
- 2008-08-21 HK HK08109379.4A patent/HK1118276A1/xx not_active IP Right Cessation
-
2010
- 2010-11-16 HR HR20100621T patent/HRP20100621T1/hr unknown
- 2010-11-25 CY CY20101101068T patent/CY1110942T1/el unknown
-
2011
- 2011-07-25 US US13/189,818 patent/US20120101109A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007010235A1 (en) | 2007-01-25 |
| NO20080053L (no) | 2008-04-16 |
| JP2009501774A (ja) | 2009-01-22 |
| US20080221124A1 (en) | 2008-09-11 |
| US20120101109A1 (en) | 2012-04-26 |
| ES2351442T3 (es) | 2011-02-04 |
| AU2006271420A1 (en) | 2007-01-25 |
| AU2006271420B2 (en) | 2010-09-23 |
| KR20080031042A (ko) | 2008-04-07 |
| EP1904490B1 (en) | 2010-09-29 |
| DK1904490T3 (da) | 2010-12-13 |
| SI1904490T1 (sl) | 2010-12-31 |
| CN101223165A (zh) | 2008-07-16 |
| ZA200800328B (en) | 2008-12-31 |
| CN101223165B (zh) | 2011-10-19 |
| CA2615596A1 (en) | 2007-01-25 |
| DE602006017220D1 (de) | 2010-11-11 |
| CY1110942T1 (el) | 2015-06-10 |
| HK1118276A1 (en) | 2009-02-06 |
| IL188389A0 (en) | 2008-04-13 |
| WO2007010235A8 (en) | 2008-03-13 |
| JP5085544B2 (ja) | 2012-11-28 |
| PT1904490E (pt) | 2010-11-18 |
| MX2008000889A (es) | 2008-03-18 |
| ATE482952T1 (de) | 2010-10-15 |
| EP1904490A1 (en) | 2008-04-02 |
| PL1904490T3 (pl) | 2011-02-28 |
| GB0514743D0 (en) | 2005-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518110A5 (hr) | ||
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| HRP20171748T1 (hr) | 6-amino kinazolina ili 3-cijano derivati kinolina, postupci priprave i njihova farmaceutska uporaba | |
| JP2024059874A (ja) | ＳＨＰ２のオクタヒドロシクロペンタ［ｃ］ピロールのアロステリック阻害剤 | |
| HRP20131051T1 (hr) | Inhibitori proteinskih kinaza | |
| HRP20100166T1 (hr) | Postupak za pripremu 2-aminotiazol-5-aromatičnih karboksamida kao inhibitora kinaze | |
| EA200800502A1 (ru) | Соединения 3-аминокарбазола, фармацевтическая композиция, содержащая указанные соединения, и способ их получения | |
| JP2014511840A5 (hr) | ||
| HRP20161498T1 (hr) | Inhibitori kinaza i njihova upotreba u liječenju raka | |
| TNSN07164A1 (en) | Quinuclidine derivatives and their use as muscarinic m3 receptor antagonists | |
| JP2011126896A5 (hr) | ||
| JP2014513704A5 (hr) | ||
| MX2010003868A (es) | Cis-imidazolinas quirales. | |
| JP2020517616A5 (hr) | ||
| JP2008533191A5 (hr) | ||
| HRP20160044T1 (hr) | Novi spojevi fenilamino izonikotinamida | |
| JP2014527042A5 (hr) | ||
| RU2015121424A (ru) | Комбинированная терапия | |
| MXPA05011739A (es) | Derivados de quinuclidina que se enlazan con los receptores muscarinicos m3. | |
| JP2014507412A5 (hr) | ||
| HRP20201681T1 (hr) | Inhibitor aurora a kinaze | |
| HRP20100678T1 (hr) | Derivati heteroariluree korisni kao inhibitori chk1 | |
| HRP20100621T1 (hr) | Etanolaminska sol od n-(metoksi-5-metilpirazin-2-il)-2-(4-[1,3,4-oksadiazol-2-il]fenil)piridin-3-sulfonamida | |
| JP2012513390A5 (hr) | ||
| EP2342198B1 (en) | A diphosphate salt of n-[6-cis-2,6-dimethylmorpholin-4yl)pyridine-3yl]-2-methyl-4'-(trifluoromethoxy)[1,1'-biphenyl]-3-carboxamide |